Cargando…
Immunotherapy for Colorectal Cancer
The recent success of anti-PD1 drugs in metastatic colorectal cancer patients with mismatch repair deficiency generated overwhelming enthusiasm for immunotherapy in the disease. However, patients with mismatch repair deficient colorectal cancer represent only a small subset of the metastatic populat...
Autores principales: | Boland, Patrick M., Ma, Wen Wee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447960/ https://www.ncbi.nlm.nih.gov/pubmed/28492495 http://dx.doi.org/10.3390/cancers9050050 |
Ejemplares similares
-
Erratum: Boland, P.M., et al. Immunotherapy for Colorectal Cancer, Cancers 2017, 9, 50
por: Boland, Patrick M., et al.
Publicado: (2020) -
Immunotherapy, Inflammation and Colorectal Cancer
por: Lichtenstern, Charles Robert, et al.
Publicado: (2020) -
Exploring immunotherapy in colorectal cancer
por: Weng, Junyong, et al.
Publicado: (2022) -
Combinatorial Immunotherapies for Metastatic Colorectal Cancer
por: Janssen, Eline, et al.
Publicado: (2020) -
Dendritic Cell-Based Immunotherapies and their Potential use in Colorectal Cancer Immunotherapy
por: Aldahlawi, Alia M., et al.
Publicado: (2021)